Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

AtriCure (ATRC) EBITDA Margin (2016 - 2025)

AtriCure (ATRC) has disclosed EBITDA Margin for 16 consecutive years, with 1.24% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1449.0% to 1.24% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.84%, a 777.0% increase, with the full-year FY2025 number at 1.84%, up 777.0% from a year prior.
  • EBITDA Margin was 1.24% for Q4 2025 at AtriCure, up from 0.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 137.64% in Q3 2021 to a low of 29.1% in Q1 2021.
  • A 5-year average of 3.45% and a median of 7.42% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 14640bps in 2021, then tumbled -15353bps in 2022.
  • AtriCure's EBITDA Margin stood at 19.77% in 2021, then soared by 83bps to 3.38% in 2022, then tumbled by -139bps to 8.07% in 2023, then tumbled by -64bps to 13.24% in 2024, then surged by 109bps to 1.24% in 2025.
  • Per Business Quant, the three most recent readings for ATRC's EBITDA Margin are 1.24% (Q4 2025), 0.33% (Q3 2025), and 3.83% (Q2 2025).